A5101690753- Immune Cell Function and Interaction
- Hepatitis C virus research
- HIV Research and Treatment
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Cytomegalovirus and herpesvirus research
- Hepatitis B Virus Studies
- Immunotherapy and Immune Responses
- Hematopoietic Stem Cell Transplantation
Great Ormond Street Hospital
2019-2022
University College London
2019-2022
University of Oxford
2013-2016
Medawar Building for Pathogen Research
2013
CD161(++) CD8(+) T cells represent a novel subset that is dominated in adult peripheral blood by mucosal-associated invariant (MAIT) cells, as defined the expression of variable-α chain 7.2 (Vα7.2)-Jα33 TCR, and IL-18Rα. Stimulation with IL-18+IL-12 known to induce IFN-γ both NK and, more limited extent, cells. Here, we show T-cell population primary triggered this mechanism. Both Vα7.2(+) Vα7.2(-) subsets responded IL-12+IL-18 stimulation, demonstrating response was not restricted MAIT but...
A prime-boost HCV vaccine strategy induces durable and broad T cell responses, characteristic of those associated with viral control.
Adenoviral vectors encoding hepatitis C virus (HCV) nonstructural (NS) proteins induce multispecific, high‐magnitude, durable CD4 + and CD8 T‐cell responses in healthy volunteers. We assessed the capacity of these vaccines to functional HCV‐specific immune determine cross‐reactivity endogenous patients with chronic HCV infection. genotype 1‐infected were vaccinated using heterologous adenoviral (ChAd3‐NSmut Ad6‐NSmut) NS a dose escalation, prime‐boost regimen, without concomitant pegylated...
An effective therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV) infection, as an adjunct to newly developed directly-acting antivirals (DAA), or prevention reinfection, would significantly reduce global burden disease associated with HCV infection. A recombinant chimpanzee adenoviral (ChAd3) vector and a modified vaccinia Ankara (MVA), encoding non-structural proteins (NSmut), used in heterologous prime/boost regimen induced multi-specific, high-magnitude, durable...
Delayed immune reconstitution is a major challenge after matched unrelated donor (MUD) stem cell transplant (SCT). In this randomized phase 2 multi-center trial, Adoptive Immunotherapy with CD25/71 allodepleted T cells to improve immunity (NCT01827579), the authors tested whether (ADTs) can safely be used alemtuzumab-based MUD SCT for hematological malignancies.